Tesaro | Date: 2012-11-13
The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase activity.
News Article | May 12, 2014
Investors pummeled Tesaro in December when an anti-nausea drug it’s been developing for cancer patients missed some key secondary goals in the first two of three late-stage trials. But today the Waltham, MA-based company bounced back when it said a third trial came through unscathed. Tesaro (NASDAQ: TSRO) said today that rolapitant, a drug it’s developing for chemotherapy-induced nausea and vomiting, hit all of its primary and secondary goals in a third and final Phase 3 study. Tesaro didn’t give any specific numbers, though; it’ll release those data at the American Society of Clinical Oncology’s annual meeting later this month. And Tesaro will incorporate the trial into the package it aims to submit to the FDA in mid-2014. Shares of Tesaro jumped about 15 percent in early trading Monday. Tesaro released the top-line data from the first two Phase 2 trials in December. The company said that rolapitant hit its primary goal—patients taking its drug in each of the two trials didn’t vomit or need rescue medication in the “delayed” phase, or between 24 and 120 hours after starting chemotherapy. Even so, Tesaro’s drug whiffed on two secondary measures. It didn’t produce a statistically significant improvement for patients in the acute phase of chemotherapy (beginning minutes to hours after starting, and lasting up to 24 hours) or overall. Shares plummeted by more than 20 percent on the news. In the latest trial, though, rolapitant didn’t miss, according to Tesaro. The primary goal was to keep cancer patients from vomiting in the delayed phase after starting chemotherapy. Tesaro said rolapitant hit that goal, and also hit statistical significance in all the secondary measures that it missed on in its other two study arms, including reducing rates of “significant nausea.” If the FDA ultimately approves rolapitant, the drug will compete with a number of other medications for chemo-induced nausea, including Merck’s aprepitant (Emend). Many of those treatments are generic, but Tesaro believes that rolapitant can differentiate itself from the competition. “We are enthusiastic about the potential for this product candidate, with a profile that may include an extended half life; convenient, single-dose oral and intravenous formulations; and a lack of CYP3A4-mediated drug interactions,” said Tesaro president Mary Lynne Hedley, in a statement. Tesaro was founded in 2010 by a group of drug developers that helped sell MGI Pharma to Japan-based Eisai for $3.9 billion in 2008. The concept behind the company was to snap up cancer drug candidates discovered by others and develop them. Tesaro, for instance, acquired rolapitant from Opko Health in 2010. The drug is its most advanced prospect.
News Article | June 21, 2011
TESARO, Inc., a Waltham, Massachusetts-based oncology-focused biopharmaceutical company, has secured $101m in Series B financing. The round was led by Kleiner Perkins Caufield & Byers, with participation from founding investor New Enterprise Associates and new backers InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management and Leerink Swann. This funding will help TESARO advance and expand its cancer product portfolio including Rolapitant, a Phase 3-ready neurokinin-1 (NK1) receptor antagonist being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV), and small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK). In conjunction with the financing, Beth Seidenberg, M.D., Partner, KPCB and Arnold Oronsky, Ph.D., General Partner, InterWest Partners have joined TESARO’s Board of Directors. The company has co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that was acquired by Eisai Co., Ltd. in 2008 for $3.9bn, and is led by CEO Lonnie Moulder.
News Article | June 23, 2015
Beth Seidenberg is a licensed physician immunologist who helped bring drugs like the asthma drug Singulair and the pain medication Vioxx to market before turning to venture capitalism. As a partner at Kleiner Perkins Caufield & Byers (KPCB), she’s helped develop companies that led to some pretty sizable exits, and we’re thrilled to announce that Seidenberg will be talking with us about her journey, Silicon Valley and her take on medical biotech startups at Disrupt SF 2015. Since Seidenberg joined KPCB in 2005, she’s incubated five companies and served as the founding CEO of two. Perhaps most notably, she navigated the exit of biotech company Flexus Biosciences, which was acquired by Bristol-Myers Squibb in February for $1.25 billion. Her other exits include Arresto Biosciences (acquired for $225 million), Atara Biotherapeutics (IPO in October 2014), Tesaro (IPO in 2012), and iPierian (acquired by Bristol-Myers Squibb in 2014 for $725 million). She also serves on the board of 9 companies, including 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO, all of which keeps her pretty busy while staying abreast of everything happening in the healthcare arena. Needless to say, Dr. Seidenberg provides a valuable skill set to KPCB and we’re lucky to have her speak at Disrupt SF. Seidenberg has a lot to say about the current state of the healthcare system, the tech industry’s love – hate relationship with the Food and Drug Administration, and how the healthcare startup landscape is changing in light of President Obama’s Affordable Care Act. And she’s playing a central role in that change. At KPCB, Seidenberg focuses on life science, investing in digital health and biotech companies who drive to improve health and the treatment of patients. Before KPCB, Seidenberg was senior vice president of development and chief medical officer of Amgen, Inc. Prior to that, she was a senior executive in research and development at Bristol-Myers Squibb as well as Merck & Co., Inc. She received her M.D. degree from the University of Miami, and did post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health. Come hear what insights Seidenberg has to share at Disrupt SF 2015, which takes place September 21 – 23 at San Francisco’s historic Pier 70. Early bird tickets to the show are still available, and you can secure your spot at the best startup event in tech by buying a ticket here.
News Article | June 21, 2011
TESARO is a privately held oncology-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products. TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein; recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline.